Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PURE BIOSCIENCE, INC.PURE · Entity 7969 | Director · 10% owner | August 20, 2024 | August 22, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PURE BIOSCIENCE, INC.
Report date August 20, 2024 · Filed August 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.07 · Expires 2034-08-20 | Direct | 125,000 |
Reported balance
After 2024-08-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-20 · Grant · Acquired 125,000 · Balance 125,000 F1: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of January 15, 2025 or the date of the Issuer's annual meeting of stockholders held in 2025, and (ii) 50% of the options will vest on the earlier of January 15, 2026 or the date of the Issuer's annual meeting of stockholders held in 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of January 15, 2025 or the date of the Issuer's annual meeting of stockholders held in 2025, and (ii) 50% of the options will vest on the earlier of January 15, 2026 or the date of the Issuer's annual meeting of stockholders held in 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2024 Filed Aug 22, 2024 22:00 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.07 | $0.00 |
DisclosureSEC source: 0001493152-24-033620 · ownership.xml · derivative · entry 1 Lee Tom Y · CIK 0001623609 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2034-08-20 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of January 15, 2025 or the date of the Issuer's annual meeting of stockholders held in 2025, and (ii) 50% of the options will vest on the earlier of January 15, 2026 or the date of the Issuer's annual meeting of stockholders held in 2026. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:19 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001209191-23-044429 · doc4.xml · derivative · entry 1 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-08-01 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2024 or January 15, 2024 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2025 or January 15, 2025. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 23:48 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 50,000 | $0.13 | $6,550.00 |
DisclosureSEC source: 0001209191-22-062029 · doc4.xml · nonDerivative · entry 1 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,001,843 Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:24 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001209191-22-052216 · doc4.xml · derivative · entry 2 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-09-30 F2 · derivative.exercise_date: The option shares shall vest and become exercisable in four equal installments December 30, 2022, March 30, 2023, June 30, 2023, and September 30, 2023. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:24 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001209191-22-052216 · doc4.xml · derivative · entry 1 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-09-30 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2023 or January 15, 2023 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2024 or January 15, 2024. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:15 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantCommon Stock | 6,000,000 | $0.15 | $900,000.00 |
DisclosureSEC source: 0001209191-22-042561 · doc4.xml · nonDerivative · entry 2 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Blessed Rock Corporation Disclosed balance after: 6,000,000 F1 · kind: This transaction was in connection with a private placement issuance by the Issuer which was approved by the Issuer's board of directors. F3 · ownership.nature: Plum Investments, L.P. holds a primary interest in Blessed Rock Corporation and may be deemed to have voting and investment control over the shares held by Blessed Rock Corporation. Mr. Lee is the general partner of Plum Investments, L.P., and has ultimate voting and investment control over the shares held by Plum Investments, L.P. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:15 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantCommon Stock | 15,741,666 | $0.15 | $2,361,249.90 |
DisclosureSEC source: 0001209191-22-042561 · doc4.xml · nonDerivative · entry 1 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Plum Investments, L.P. Disclosed balance after: 29,143,617 F1 · kind: This transaction was in connection with a private placement issuance by the Issuer which was approved by the Issuer's board of directors. F2 · ownership.nature: Mr. Lee is the general partner of Plum Investments, L.P., and has ultimate voting and investment control over the shares held by Plum Investments, L.P. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 01:49 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 185,000 | $0.20 | $36,630.00 |
DisclosureSEC source: 0001209191-22-020677 · doc4.xml · nonDerivative · entry 3 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,951,843 F1 · price: This transaction was executed in multiple purchases through a purchase order executed by a broker-dealer at prices ranging from $0.194 to $0.1998. The price reported in this column reflects the weighted average purchase price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 17, 2022 Filed Mar 23, 2022 01:49 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 13,250 | $0.18 | $2,371.75 |
DisclosureSEC source: 0001209191-22-020677 · doc4.xml · nonDerivative · entry 2 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,766,843 Read SEC document |
| March 16, 2022 Filed Mar 23, 2022 01:49 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 21,227 | $0.18 | $3,820.86 |
DisclosureSEC source: 0001209191-22-020677 · doc4.xml · nonDerivative · entry 1 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,753,593 Read SEC document |
| June 18, 2021 Filed Jun 23, 2021 00:24 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001209191-21-042593 · doc4.xml · derivative · entry 8 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-06-18 F5 · derivative.exercise_date: The option shares shall vest and become exercisable in four equal installments on September 18, 2021, December 18, 2021, March 18, 2022 and June 18, 2022. Read SEC document |
| June 18, 2021 Filed Jun 23, 2021 00:24 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001209191-21-042593 · doc4.xml · derivative · entry 7 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-06-18 F4 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2022 or January 15, 2022 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2023 or January 15, 2023. Read SEC document |
| June 16, 2021 Filed Jun 23, 2021 00:24 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 35,998 | $0.43 | $15,515.14 |
DisclosureSEC source: 0001209191-21-042593 · doc4.xml · nonDerivative · entry 1 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,732,366 F1 · price: This transaction was executed in multiple purchases through a purchase order executed by a broker-dealer at prices ranging from $0.425 to $0.438. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 24, 2020 Filed Dec 28, 2020 22:44 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 851 | $0.65 | $553.15 |
DisclosureSEC source: 0001209191-20-065235 · doc4.xml · nonDerivative · entry 5 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,696,368 Read SEC document |
| December 22, 2020 Filed Dec 28, 2020 22:44 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 45,299 | $0.66 | $29,987.94 |
DisclosureSEC source: 0001209191-20-065235 · doc4.xml · nonDerivative · entry 4 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,695,517 F2 · price: This transaction was executed in multiple purchases through a purchase order executed by a broker-dealer at prices ranging from $0.64 to $0.68. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 21, 2020 Filed Dec 28, 2020 22:44 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 7,859 | $0.68 | $5,344.12 |
DisclosureSEC source: 0001209191-20-065235 · doc4.xml · nonDerivative · entry 3 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,650,218 Read SEC document |
| December 17, 2020 Filed Dec 28, 2020 22:44 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 4,712 | $0.65 | $3,062.80 |
DisclosureSEC source: 0001209191-20-065235 · doc4.xml · nonDerivative · entry 2 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,642,359 Read SEC document |
| December 16, 2020 Filed Dec 28, 2020 22:44 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 20,000 | $0.67 | $13,300.00 |
DisclosureSEC source: 0001209191-20-065235 · doc4.xml · nonDerivative · entry 1 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,637,647 F1 · price: This transaction was executed in multiple purchases through a purchase order executed by a broker-dealer at prices ranging from $0.66 to $0.67. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 21:37 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | OtherCommon Stock | 10,732,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-039138 · doc4.xml · nonDerivative · entry 1 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Plum Investments, L.P. Disclosed balance after: 13,401,951 F1 · kind: The shares were distributed on a pro rata basis by Plum Investments, L.P., for no consideration. F2 · ownership.nature: Mr. Lee is the general partner of Plum Investments, L.P., and has ultimate voting and investment control over the shares held by Plum Investments, L.P. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 00:58 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 13,124 | $1.72 | $22,573.28 |
DisclosureSEC source: 0001209191-20-038334 · doc4.xml · nonDerivative · entry 3 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,617,647 F2 · price: This transaction was executed in multiple purchases through a purchase order executed by a broker-dealer at prices ranging from $1.61 to $1.82. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 00:58 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 10,000 | $1.85 | $18,500.00 |
DisclosureSEC source: 0001209191-20-038334 · doc4.xml · nonDerivative · entry 2 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,604,523 Read SEC document |
| June 18, 2020 Filed Jun 23, 2020 00:58 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 30,000 | $1.75 | $52,497.00 |
DisclosureSEC source: 0001209191-20-038334 · doc4.xml · nonDerivative · entry 1 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,594,523 F1 · price: This transaction was executed in multiple purchases through a purchase order executed by a broker-dealer at prices ranging from $1.62 to $1.83. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 22:19 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 26,876 | $1.61 | $43,135.98 |
DisclosureSEC source: 0001209191-20-037706 · doc4.xml · nonDerivative · entry 4 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,564,523 F4 · price: This transaction was executed in multiple purchases through a purchase order executed by a broker-dealer at prices ranging from $1.38 to $1.70. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:19 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 70,000 | $1.62 | $113,330.00 |
DisclosureSEC source: 0001209191-20-037706 · doc4.xml · nonDerivative · entry 3 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,537,647 F3 · price: This transaction was executed in multiple purchases through a purchase order executed by a broker-dealer at prices ranging from $1.40 to $1.74. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 15, 2020 Filed Jun 18, 2020 22:19 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 60,000 | $1.82 | $109,200.00 |
DisclosureSEC source: 0001209191-20-037706 · doc4.xml · nonDerivative · entry 2 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,467,647 F2 · price: This transaction was executed in multiple purchases through a purchase order executed by a broker-dealer at prices ranging from $1.72 to $1.88. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 12, 2020 Filed Jun 18, 2020 22:19 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 45,157 | $1.91 | $86,204.71 |
DisclosureSEC source: 0001209191-20-037706 · doc4.xml · nonDerivative · entry 1 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,407,647 F1 · price: This transaction was executed in multiple purchases through a purchase order executed by a broker-dealer at prices ranging from $1.89 to $1.94. The price reported in this column reflects the weighted average sale price. The Reporting Person will provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2020 Filed May 19, 2020 22:55 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-20-030696 · doc4.xml · derivative · entry 2 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-05-15 F1 · derivative.exercise_date: The option shares shall vest and become exercisable in four equal installments on August 15, 2020, November 15, 2020, February 15, 2021 and May 15, 2021. Read SEC document |
| May 15, 2020 Filed May 19, 2020 22:55 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-20-030696 · doc4.xml · derivative · entry 1 Lee Tom Y · CIK 0001623609 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-05-15 F1 · derivative.exercise_date: The option shares shall vest and become exercisable in four equal installments on August 15, 2020, November 15, 2020, February 15, 2021 and May 15, 2021. Read SEC document |
| March 09, 2020 Filed Mar 12, 2020 22:03 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantCommon Stock | 2,243,103 | $0.29 | $650,499.87 |
DisclosureSEC source: 0001209191-20-018612 · doc4.xml · nonDerivative · entry 3 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Plum Investments, L.P. Disclosed balance after: 24,134,173 F4 · kind: This transaction was in connection with a private placement issuance by the Issuer which was approved by the Issuer's board of directors. F2 · ownership.nature: Mr. Lee is the general partner and sole limited partner of Plum Investments, L.P., and has ultimate voting and investment control over the shares held by Plum Investments, L.P. Read SEC document |
| February 14, 2020 Filed Mar 12, 2020 22:03 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GiftCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-018612 · doc4.xml · nonDerivative · entry 2 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Tessa Melody Shin Trust Dated February 12, 2020 Disclosed balance after: 1,000,000 F1 · kind: This transactions represent a gift for no value by the Reporting Person. F3 · ownership.nature: Mr. Lee is a trustee of the Kamika Shay Lee Trust Dated July 1, 2019, Karissa Shay Lee Trust Dated July 1, 2019 and Tessa Melody Shin Trust Dated February 12, 2020 and has voting and dispositive power with respect to these shares Read SEC document |
| February 14, 2020 Filed Mar 12, 2020 22:03 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GiftCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-018612 · doc4.xml · nonDerivative · entry 1 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Plum Investments, L.P. Disclosed balance after: 21,891,070 F1 · kind: This transactions represent a gift for no value by the Reporting Person. F2 · ownership.nature: Mr. Lee is the general partner and sole limited partner of Plum Investments, L.P., and has ultimate voting and investment control over the shares held by Plum Investments, L.P. Read SEC document |
| January 29, 2020 Filed Feb 1, 2020 01:38 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-005909 · doc4.xml · derivative · entry 1 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-01-29 F1 · derivative.exercise_date: The option shares shall vest and become exercisable in eight equal quarterly installments beginning on April 30, 2020. Read SEC document |
| December 19, 2019 Filed Feb 10, 2020 23:51 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 754,884 | $0.29 | $218,161.48 |
DisclosureSEC source: 0001209191-20-008081 · doc4.xml · nonDerivative · entry 1 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Plum Investments, L.P. Disclosed balance after: 22,891,070 F1 · ownership.nature: Mr. Lee is the general partner and sole limited partner of Plum Investments, L.P., and has ultimate voting and investment control over the shares held by Plum Investments, L.P. Read SEC document |
| October 02, 2019 Filed Oct 3, 2019 22:28 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 1,000,000 | $0.29 | $290,000.00 |
DisclosureSEC source: 0001209191-19-052410 · doc4.xml · nonDerivative · entry 1 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Plum Investments, L.P. Disclosed balance after: 22,136,186 F1 · ownership.nature: Mr. Lee is the general partner and sole limited partner of Plum Investments, L.P., and has ultimate voting and investment control over the shares held by Plum Investments, L.P. Read SEC document |
| October 02, 2019 Filed Feb 6, 2020 23:00 UTC Amendment | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantCommon Stock | 1,000,000 | $0.29 | $290,000.00 |
DisclosureSEC source: 0001209191-20-007271 · doc4a.xml · nonDerivative · entry 1 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Plum Investments, L.P. Disclosed balance after: 22,136,186 F1 · kind: The previously filed Form 4 report incorrectly stated the Code as P. The transaction was in connection with a private placement issuance by the Issuer which was approved by the Issuer's board of directors and therefore the transaction should have been reported under the Code A. F2 · ownership.nature: Mr. Lee is the general partner and sole limited partner of Plum Investments, L.P., and has ultimate voting and investment control over the shares held by Plum Investments, L.P. Read SEC document |
| October 01, 2019 Filed Oct 3, 2019 22:28 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.29 | $0.00 |
DisclosureSEC source: 0001209191-19-052410 · doc4.xml · derivative · entry 6 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-10-01 F3 · derivative.exercise_date: The option shares shall vest and become exercisable in four equal installments on January 1, 2020, April 1, 2020, July 1, 2020 and October 1, 2020. Read SEC document |
| July 02, 2019 Filed Aug 6, 2019 22:09 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GiftCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-044879 · doc5.xml · nonDerivative · entry 4 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Karissa Shay Lee Trust Dated July 1, 2019 Disclosed balance after: 1,000,000 F1 · kind: This transactions represent a gift for no value by the Reporting Person. F3 · ownership.nature: Mr. Lee is a trustee of the Kamika Shay Lee Trust Dated July 1, 2019 and Karissa Shay Lee Trust Dated July 1, 2019 and has voting and dispositive power with respect to these shares. Read SEC document |
| July 02, 2019 Filed Aug 6, 2019 22:09 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GiftCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-044879 · doc5.xml · nonDerivative · entry 3 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Plum Investments, L.P. Disclosed balance after: 21,136,186 F1 · kind: This transactions represent a gift for no value by the Reporting Person. F3 · ownership.nature: Mr. Lee is a trustee of the Kamika Shay Lee Trust Dated July 1, 2019 and Karissa Shay Lee Trust Dated July 1, 2019 and has voting and dispositive power with respect to these shares. Read SEC document |
| July 01, 2019 Filed Aug 6, 2019 22:09 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GiftCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-044879 · doc5.xml · nonDerivative · entry 2 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Kamika Shay Lee Trust Dated July 1, 2019 Disclosed balance after: 1,000,000 F1 · kind: This transactions represent a gift for no value by the Reporting Person. F3 · ownership.nature: Mr. Lee is a trustee of the Kamika Shay Lee Trust Dated July 1, 2019 and Karissa Shay Lee Trust Dated July 1, 2019 and has voting and dispositive power with respect to these shares. Read SEC document |
| July 01, 2019 Filed Aug 6, 2019 22:09 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GiftCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-044879 · doc5.xml · nonDerivative · entry 1 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Plum Investments, L.P. Disclosed balance after: 22,136,186 F1 · kind: This transactions represent a gift for no value by the Reporting Person. F2 · ownership.nature: Mr. Lee is the general partner and sole limited partner of Plum Investments, L.P., and has ultimate voting and investment control over the shares held by Plum Investments, L.P. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 22:37 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | OtherWarrant · Derivative | 2,133,333 | Not disclosed Strike: $0.35 | Not disclosed |
DisclosureSEC source: 0001209191-19-012187 · doc4.xml · derivative · entry 6 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Plum Investments, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,133,333 shares Expires 2019-08-29 F3 · price: Represents a private purchase under the terms of a Securities Transfer Agreement between Reporting Person and Franchise Brands, LLC for an aggregate purchase price of $8,399,999.70. F1 · ownership.nature: Mr. Lee is the general partner and sole limited partner of Plum Investments, L.P., and has ultimate voting and investment control over the shares held by Plum Investments, L.P. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 22:37 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantWarrant · Derivative | 2,133,333 | Not disclosed Strike: $0.35 | Not disclosed |
DisclosureSEC source: 0001209191-19-012187 · doc4.xml · derivative · entry 5 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Plum Investments, L.P. Disclosed balance after: 2,133,333 Underlying: Common Stock · 2,133,333 shares Expires 2019-08-29 F2 · kind: The reported transactions relate to an amendment of the exercise price of an outstanding warrant from $0.75 per share to $0.35 per share of Common Stock, contingent upon the Reporting Person immediately exercising the Warrant. As a result of this amendment, the outstanding warrant was deemed canceled and a replacement warrant was issued for the same number of shares of Common Stock, but with the reduced exercise price. The outstanding warrant was originally issued on December 2017. F3 · price: Represents a private purchase under the terms of a Securities Transfer Agreement between Reporting Person and Franchise Brands, LLC for an aggregate purchase price of $8,399,999.70. F1 · ownership.nature: Mr. Lee is the general partner and sole limited partner of Plum Investments, L.P., and has ultimate voting and investment control over the shares held by Plum Investments, L.P. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 22:37 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | Disposition to issuerWarrant · Derivative | 2,133,333 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001209191-19-012187 · doc4.xml · derivative · entry 4 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Plum Investments, L.P. Disclosed balance after: 0 Underlying: Common Stock · 2,133,333 shares Expires 2019-08-29 F2 · kind: The reported transactions relate to an amendment of the exercise price of an outstanding warrant from $0.75 per share to $0.35 per share of Common Stock, contingent upon the Reporting Person immediately exercising the Warrant. As a result of this amendment, the outstanding warrant was deemed canceled and a replacement warrant was issued for the same number of shares of Common Stock, but with the reduced exercise price. The outstanding warrant was originally issued on December 2017. F3 · price: Represents a private purchase under the terms of a Securities Transfer Agreement between Reporting Person and Franchise Brands, LLC for an aggregate purchase price of $8,399,999.70. F1 · ownership.nature: Mr. Lee is the general partner and sole limited partner of Plum Investments, L.P., and has ultimate voting and investment control over the shares held by Plum Investments, L.P. Read SEC document |
| February 19, 2019 Filed Feb 21, 2019 22:37 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | OtherCommon Stock | 2,133,333 | $0.35 | $746,666.55 |
DisclosureSEC source: 0001209191-19-012187 · doc4.xml · nonDerivative · entry 1 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Plum Investments, L.P. Disclosed balance after: 23,136,186 F1 · ownership.nature: Mr. Lee is the general partner and sole limited partner of Plum Investments, L.P., and has ultimate voting and investment control over the shares held by Plum Investments, L.P. Read SEC document |
| August 16, 2018 Filed Aug 20, 2018 23:10 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 2,336,187 | $0.45 | $1,051,284.15 |
DisclosureSEC source: 0001209191-18-047688 · doc4.xml · nonDerivative · entry 1 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Plum Investments, L.P. Disclosed balance after: 21,002,853 F1 · shares: The shares were purchased in connection with the Issuer's private placement financing for cash and the cancellation of certain of the Reporting Person's existing indebtedness to the Issuer. F2 · ownership.nature: Mr. Lee is the general partner and sole limited partner of Plum Investments, L.P., and has ultimate voting and investment control over the shares held by Plum Investments, L.P. Read SEC document |
| February 26, 2018 Filed Mar 1, 2018 00:17 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-18-014698 · doc4.xml · derivative · entry 1 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2023-02-27 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2019 or January 15, 2019 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2020 or January 15, 2020. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 22:12 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseWarrant · Derivative | 2,133,333 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001209191-17-067662 · doc4.xml · derivative · entry 4 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Plum Investments, L.P. Disclosed balance after: 2,133,333 Underlying: Common Stock · 2,133,333 shares Expires 2019-08-29 F1 · kind: Represents a private purchase under the terms of a Securities Transfer Agreement between Reporting Person and Franchise Brands, LLC for an aggregate purchase price of $8,399,999.70. F1 · price: Represents a private purchase under the terms of a Securities Transfer Agreement between Reporting Person and Franchise Brands, LLC for an aggregate purchase price of $8,399,999.70. F2 · ownership.nature: Mr. Lee is the general partner and sole limited partner of Plum Investments, L.P., and has ultimate voting and investment control over the shares held by Plum Investments, L.P. Read SEC document |
| December 29, 2017 Filed Dec 29, 2017 22:12 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | PurchaseCommon Stock | 18,666,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-067662 · doc4.xml · nonDerivative · entry 1 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Plum Investments, L.P. Disclosed balance after: 18,666,666 F1 · kind: Represents a private purchase under the terms of a Securities Transfer Agreement between Reporting Person and Franchise Brands, LLC for an aggregate purchase price of $8,399,999.70. F1 · price: Represents a private purchase under the terms of a Securities Transfer Agreement between Reporting Person and Franchise Brands, LLC for an aggregate purchase price of $8,399,999.70. F2 · ownership.nature: Mr. Lee is the general partner and sole limited partner of Plum Investments, L.P., and has ultimate voting and investment control over the shares held by Plum Investments, L.P. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 22:13 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | Exercise / conversionWarrant · Derivative | 166,666 | Not disclosed Strike: $0.40 | Not disclosed |
DisclosureSEC source: 0001209191-17-054169 · doc4.xml · derivative · entry 8 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Wife Disclosed balance after: 0 Underlying: Common Stock · 166,666 shares Expires 2017-09-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: In accordance with the terms of the Issuer's tender offer, the Reporting Person exercised her 2015 Warrant in full and in cash on September 25, 2017. F4 · price: In accordance with the terms of the Issuer's tender offer, the Reporting Person exercised her 2015 Warrant in full and in cash on September 25, 2017. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 22:13 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantWarrant · Derivative | 166,666 | Not disclosed Strike: $0.40 | Not disclosed |
DisclosureSEC source: 0001209191-17-054169 · doc4.xml · derivative · entry 7 Lee Tom Y · CIK 0001623609 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Wife Disclosed balance after: 166,666 Underlying: Common Stock · 166,666 shares Expires 2017-09-25 F3 · kind: On September 25, 2017, the Issuer completed the initial closing of a tender offer in which the Issuer offered to amend the terms of the outstanding warrants the Issuer issued to investors participating in private placement financings the Issuer completed on August 29, 2014 (the "2014 Warrants"), on November 23, 2015 (the "2015 Warrants") and on January 23, 2017 (the "2017 Warrants"). As part of the tender offer and in order to raise funds to support its continued operations, the Issuer offered to reduce the respective exercise prices of the 2014, 2015 and 2017 Warrants if the holders agreed to exercise their Warrants in cash by September 25, 2017. The Reporting Person holds a 2015 Warrant and elected to participate in the Issuer's tender offer. As a result, the exercise price and the expiration date, among other terms, of the 2015 Warrant held by the Reporting Person were amended. F3 · price: On September 25, 2017, the Issuer completed the initial closing of a tender offer in which the Issuer offered to amend the terms of the outstanding warrants the Issuer issued to investors participating in private placement financings the Issuer completed on August 29, 2014 (the "2014 Warrants"), on November 23, 2015 (the "2015 Warrants") and on January 23, 2017 (the "2017 Warrants"). As part of the tender offer and in order to raise funds to support its continued operations, the Issuer offered to reduce the respective exercise prices of the 2014, 2015 and 2017 Warrants if the holders agreed to exercise their Warrants in cash by September 25, 2017. The Reporting Person holds a 2015 Warrant and elected to participate in the Issuer's tender offer. As a result, the exercise price and the expiration date, among other terms, of the 2015 Warrant held by the Reporting Person were amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.